With so many lives at stake, (typo on earlier version)One must believe that the Board Members and Management are making efforts behind the scenes to get SQI's Respiratory Products to scale as quickly as possible. The impact to both the company and to fellow human beings is beyond significant.
RALI-Dx for ER's and Rali-fast for ICUs are likely billion dollar global opportunities each.
TOR-Dx is another huge opportunity, with the impact on those waiting for an organ replacement in many cases being the difference of life and death. The momentum here is huge, and with the support of Shaf Keshavjee and his UHN team this is a big win for all. Shaf's global network follows in his footsteps...Toronto leads the way when it comes to establishing protocols for Lung evaluation and transplants (SQI plays a growing role).
After Lungs, UHN & SQI moves on to include other key organs using adapted versions of TOR-Dx. While Lungs represent greater than a hundred million dollar opportunity, once other organs are included it will likely be between a quarter and half billions dollars. Think of the lives impacted here. This is about a lot more than money, and for all the scientists and developers this has extra special meaning too.
The OWLSTONE Breath based tests are also a great product extension. This could be another hundred million or more opportunity, and again impacts the lives of many.
We need to get the story out so that those that can influence quicker support and adoption are well aware of SQI's unique offerings and the significant impact they are set to make. Increased Government support and involvement may follow.
The need is great and SQI has an important contribution to make. Its time to let the story breathe...